C.M. Bidwell & Associates’s CRISPR Therapeutics CRSP Stock Holding History

C.M. Bidwell & Associates’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$856	Hold	18	–	–	﹤0.01%	435
2025 Q4	$944	Hold	18	–	–	﹤0.01%	426
2025 Q3	$1.17K	Hold	18	–	–	﹤0.01%	427
2025 Q2	$876	Hold	18	–	–	﹤0.01%	391
2025 Q1	$613	Hold	18	–	–	﹤0.01%	399
2024 Q4	$708	Sell	18 -38	-68%	-$1.79K	﹤0.01%	440
2024 Q3	$2.63K	Sell	56 -736	-93%	-$37.3K	﹤0.01%	422
2024 Q2	$42.8K	Hold	792	–	–	0.03%	234
2024 Q1	$54K	Sell	792 -10	-1%	-$716	0.04%	221
2023 Q4	$50.2K	Sell	802 -2,317	-74%	-$128K	0.04%	217
2023 Q3	$142K	Buy	3,119 +695	+29%	+$35.9K	0.11%	162
2023 Q2	$136K	Buy	2,424 +724	+43%	+$41.1K	0.1%	181
2023 Q1	$76.9K	Buy	1,700 +1,644	+2,936%	+$79.8K	0.06%	259
2022 Q4	$2.28K	Buy	56 +38	+211%	+$2.02K	﹤0.01%	436
2022 Q3	$1K	Sell	18 -35	-66%	-$2.54K	﹤0.01%	448
2022 Q2	$3K	Hold	53	–	–	﹤0.01%	406
2022 Q1	$3K	Buy	53 +28	+112%	+$1.76K	﹤0.01%	438
2021 Q4	$2K	Buy	+25	New	+$2.18K	﹤0.01%	515

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

C.M. Bidwell & Associates's CRSP Position: Q1 2026 in Review

C.M. Bidwell & Associates held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 18 shares worth $856. The position accounts for ﹤0.01% of the portfolio, ranked #435.

C.M. Bidwell & Associates first reported a position in CRSP in Q4 2021 and has held it in 18 quarters since. The position peaked at $142K in Q3 2023. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

C.M. Bidwell & Associates held 18 shares of CRISPR Therapeutics worth $856 as of Q1 2026.
C.M. Bidwell & Associates left its CRISPR Therapeutics share count unchanged in Q1 2026.
CRISPR Therapeutics made up ﹤0.01% of C.M. Bidwell & Associates's portfolio in Q1 2026, its #435 holding.
C.M. Bidwell & Associates first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 18 quarters since.
C.M. Bidwell & Associates's CRISPR Therapeutics position peaked at $142K in Q3 2023.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2026, filed 15 May 2026.